Apricus Biosciences, Inc. (Nasdaq:APRI)

December 18, 2011 8:40 PM
Apricus Biosciences, Inc. (Nasdaq:APRI)

Apricus Biosciences, Inc. (Nasdaq:APRI)

SAN DIEGO, Aug. 11, 2011 (GLOBE NEWSWIRE) – Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI) (http://www.apricusbio.com) announced today that Chairman, President and Chief Executive Officer, Dr. Bassam Damaj, was interviewed recently by the CEO Roadshow financial network (http://www.ceoroadshow/). During the interview, Dr. Damaj reported on plans for the Company’s pipeline, including the proposed commercialization in Canada and Europeof Vitaros®, a topical treatment for erectile dysfunction. Disclaimer

December 18, 2011 8:40 PMWatch now
InVivo Therapeutics (NVIV.OB)

InVivo Therapeutics (NVIV.OB)

Interview with Mr. Frank Reynolds, Chairman and CEO of InVivo Therapeutics (NVIV.OB). About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is a Cambridge, MA medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital in Boston. For more information on InVivo Therapeutics, please visit invivotherapeutics.com. Disclaimer

December 18, 2011 8:16 PMWatch now
Access Pharmaceuticals OTCBB:ACCP

Access Pharmaceuticals OTCBB:ACCP

Interview with Access Pharmaceuticals CEO, Mr. Jeff Davis discussing recent events at the company. Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com. Disclaimer

December 18, 2011 8:00 PMWatch now

Join Us On Twitter

  • CeoRoadShow.com
    MediSwipe Inc. (OTCBB:MWIP) announces over 2 Million$ in merchant processing transactions stock up 30%, this one could run. Read yahoo news 36 days ago
  • CeoRoadShow.com
    Saur Energy (SENY) breaks .80 on high volume today. Stock breaks 30% gains in 30 days. 38 days ago
  • Vesta Digital
    #GACR http://t.co/ZMhxDvRJ 41 days ago

Copyright © 2012 CEO Roadshow All Rights Reserved.    Terms of Use  •  Privacy Policy  •  Site Map

Viestly
CEORoadshow.com is a compensated financial public relations company which is committed to producing the highest-quality insight and analysis of penny stocks, emerging technology stocks, small cap stocks and helping investors make informed decisions. Trade stocks Jim Cramer style.